Journals / Turkish Journal of Gastroenterology / 2019 / Cilt: 30 - Sayı: 8

A bioactive product lipoxin A4 attenuates liver fibrosis in an experimental model by regulating immune response and modulating the expression of regeneration genes

Pages
745–757
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

LXA4 may be therapeutically beneficial in liver fibrosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: Lipoxin A4 (LXA4), an anti-inflammatory lipid mediator, regulates leukocyte cellular activity and activates genetranscription.
📊
Key Findings & Data:The therapeutic effect of LXA4 on liver fibrosis and its mechanism on the immune system are largely unknown.
💡
Conclusion & Impact:LXA4 may be therapeutically beneficial in liver fibrosis.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background/Aims: Lipoxin A4 (LXA4), an anti-inflammatory lipid mediator, regulates leukocyte cellular activity and activates genetranscription. The therapeutic effect of LXA4 on liver fibrosis and its mechanism on the immune system are largely unknown. Becausethe regenerative capacity of hepatocytes in acute and chronic liver failure models of mouse increases by silencing MKK4, we aimed toinvestigate the effect of parenteral administration of LXA4 on the genes responsible for regeneration of liver, namely MKK4, MKK7, andATF2, and visualize the therapeutic effects in an experimental model.Materials and Methods: Fibrosis was induced in mice by administration of thioacetamide (TAA). LXA4 was administered during the lasttwo weeks of fibrosis induction. The fibrosis level was measured by Knodell scoring. The liver function was measured by analyzing serumALT, AST, and AP levels. Expression levels of genes responsible for liver fibrosis (TGF-α) and cell regeneration (MKK4, MKK7, and ATF2)have been measured by RT-PCR analysis. Inflammatory and anti-inflammatory cytokine levels were measured in serum samples andliver homogenates by Enzyme Linked Immunosorbent Assay (ELISA). Ultrathin sections were examined using a transmission electronmicroscope and analyzed.Results: We observed significant healing in liver of the LXA4-treated group, histologically. This finding was in parallel with reduction ofserum ALT, AST, but not AP levels. TGF-α and MKK4 expressions were significantly reduced in the LXA4-treated group. Administrationof LXA4 caused significant elevation of IL-10 in systemic circulation; however, that elevation was not detected in liver homogenates.Nevertheless, significant reductions in TNF-α and IL-17 have been observed.Conclusion: The anti-inflammatory effect of LXA4 maintains the regenerative capacity of liver during fibrosis in an experimental liverfibrosis model. LXA4 may be therapeutically beneficial in liver fibrosis.

🔖

Cite This Article

KURTOĞLU, E. L., KAYHAN, B., GÜL, M., KAYHAN, B., KAYHAN, M. A., KARACA, Z. M., YEŞİLADA, E., YILMAZ, S. (2019). A bioactive product lipoxin A4 attenuates liver fibrosis in an experimental model by regulating immune response and modulating the expression of regeneration genes. Turkish Journal of Gastroenterology, Cilt: 30 - Sayı: 8, 745–757. https://ajindex.com/articles/410086

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Henderson NC, Iredale JP. Liver fibrosis: Cellular mechanism of progression and resolution. Clin Sci 2007
  2. [CrossRef] 2. Parsons CJ, Takashima M, Rippe RA. Molecular mechanisms of hepatic fibrogenesis. J Gastroenterol Hepatol 2007
  3. 22(S1): S79-S84. [CrossRef] 3. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005
  4. [CrossRef] 4. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011
  5. [CrossRef] 5. Arias IM. The Liver: Biology and pathobiology. New York, Raven Press
  6. Malhi H, Gores GJ. Cellular and molecular mechanisms of liver injury. Gastroenterology 2008
  7. [CrossRef] 7. Li D, Friedman SL. Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy. J Gastroenterol Hepatol 1999
  8. [CrossRef] 8. Xu R, Zhang Z, Wang FS. Liver fibrosis: mechansims of immune-mediated liver injury. Cell Mol Immunol 2012
  9. [CrossRef] 9. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011
  10. [CrossRef] 10. Satopathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroeterol Hepatol 2007
  11. Yamaguchi N, Mezaki Y, Miura M, et al. Antiproliferative and proapoptotic effects of tocopherol and tocol on activated hepatic stellate cells. J Nutr Sci Vitaminol (Tokyo) 2011
  12. [CrossRef] 12. Ahmad A, Ahmad R. Understanding the mechanism of hepatic fibrosis and potential therapeutic approaches. Saudi J Gastroenterol 2012
  13. [CrossRef] 13. Schwab JM, Serhan CN. Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol 2006
  14. [CrossRef] 14. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol 2005
  15. [CrossRef] 15. Starkel P. Animal models for the study of hepatic fibrosis. Best Prac Res Clin Gastroenterol 2011
  16. [CrossRef] 16. Souza MC, Pauda TA, Torres ND, et al. Lipoxin A4 attenuates endothelial dysfunction during experimental cerebral malaria. Int Immunopharmacol 2015
  17. [CrossRef] 17. Xu Z, Zhao F, Lin F, Chen J, Huang Y. Lipoxin A4 Inhibits the Development of Endometriosis in Mice: The Role of Anti-Inflammation and Anti-Angiogenesis. Am J Reprod Immunol 2012
  18. [CrossRef] 18. Huang WC, Shen J